D

DBV Technologies SA

D
DBVT
USD
-0.0396
(-5.1156%)
Market Closed
1,414.00
Volume
-1.28836
EPS
-
Div Yield
-0.807143
P/E
70,669,518.67
Market Cap
Today
-3.3807%
1 Week
-5.311%
1 Month
8.015%
6 Months
-45.187%
12 Months
-62.100%
Year To Date
-61.232%
All Time
0%

Title:
DBV Technologies SA

Sector:
Healthcare
Industry:
Biotechnology
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.
Do you need help or have a question?